Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses
The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibo...
Gespeichert in:
| Veröffentlicht in: | Medical microbiology and immunology 2024-12, Vol.213 (1), p.24-24, Article 24 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24 |
|---|---|
| container_issue | 1 |
| container_start_page | 24 |
| container_title | Medical microbiology and immunology |
| container_volume | 213 |
| creator | Chang, Fangfang Wu, Qian Hu, Yabin Pan, Zhendong Liu, Yong-Chen Li, Yue-Zhou Bostina, Mihnea Liu, Wenpei Zhao, Ping Qu, Xiaowang Li, Yi-Ping |
| description | The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). A bsAb 5-HI showed a high binding capability to the S1 subunit of spike and exhibited breadth and potency against pseudotyped SARS-CoV-2 variants of concerns (VOCs) and SARS-related-CoVs (SARSr-CoVs), with half maximal effective concentration (EC
50
) of 0.028–3.444 nM and 50% inhibitory concentration (IC
50
) of 0.008-0.800 nM. In addition, it retained neutralization potency against the peudotyped virus of recently prevalent JN.1 strain (IC
50
, 12.74 nM). We found that the parental antibodies showed weak or no binding to the receptor binding domain (RBD) of the SARS-CoV, EG.5.1, and JN.1. However, the 5-HI maintained the binding with RBD and prevented the binding between hACE2 and RBD (IC
50
for the RBD of SARS-CoV, 1.067 nM; EG.5.1, 0.423 nM; JN.1, 0.223 nM). In neutralization assays with the authentic virus, we found that the 5-HI effectively neutralized Omicron variants XBB.1.5 (IC
50
, 0.308 nM), EG.5.1 (IC
50
, 0.129 nM), and JN.1 (IC
50
, 13.692 nM), while its parental antibodies showed weakened or no neutralization. Therefore, the 5-HI represents a promising candidate for further development in the treatment and prevention of ongoing evolved SARS-CoV-2 VOCs and other SARSr-CoVs that potentially emerge in the future. |
| doi_str_mv | 10.1007/s00430-024-00809-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3154183463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3128745288</sourcerecordid><originalsourceid>FETCH-LOGICAL-c289t-5f830a5f836b6c0c0edc35eff055787e382af1c38aec37962e66f3c309957c453</originalsourceid><addsrcrecordid>eNqNkc9rFDEUx4Modq3-Ax5kwEsv0ZdfM8mxLPUHFIS2eg3ZzJttym6yJjOVHvq_m9mtCh5KLwm893mfkPcl5C2DDwyg-1gApAAKXFIADYaaZ2TBpOCUacGekwUIAKqVlkfkVSk3AKxrObwkR8IoDqozC3J_FtchImbsm1UoO_RhCL5xcQyr1Acsza8wXjcYr130M5PR9bXgYt_s0ojR3zVu7UIsY3N5enFJl-kH5c2ty6E6yp7b1zNu3FgFPuUU3W3IU8HymrwY3Kbgm4f7mHz_dHa1_ELPv33-ujw9p55rM1I1aAFuPttV68ED9l4oHAZQqtMdCs3dwLzQDr3oTMuxbQfhBRijOi-VOCYnB-8up58TltFuQ_G42biIaSpWMCXrzmQrnoBy3UnFta7o-__QmzTlWD8yU60UWppZyA-Uz6mUjIPd5bB1-c4ysHOO9pCjrTnafY7W1KF3D-pptcX-78if4CogDkCprbjG_O_tR7S_AU41p-c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126438493</pqid></control><display><type>article</type><title>Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chang, Fangfang ; Wu, Qian ; Hu, Yabin ; Pan, Zhendong ; Liu, Yong-Chen ; Li, Yue-Zhou ; Bostina, Mihnea ; Liu, Wenpei ; Zhao, Ping ; Qu, Xiaowang ; Li, Yi-Ping</creator><creatorcontrib>Chang, Fangfang ; Wu, Qian ; Hu, Yabin ; Pan, Zhendong ; Liu, Yong-Chen ; Li, Yue-Zhou ; Bostina, Mihnea ; Liu, Wenpei ; Zhao, Ping ; Qu, Xiaowang ; Li, Yi-Ping</creatorcontrib><description>The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). A bsAb 5-HI showed a high binding capability to the S1 subunit of spike and exhibited breadth and potency against pseudotyped SARS-CoV-2 variants of concerns (VOCs) and SARS-related-CoVs (SARSr-CoVs), with half maximal effective concentration (EC
50
) of 0.028–3.444 nM and 50% inhibitory concentration (IC
50
) of 0.008-0.800 nM. In addition, it retained neutralization potency against the peudotyped virus of recently prevalent JN.1 strain (IC
50
, 12.74 nM). We found that the parental antibodies showed weak or no binding to the receptor binding domain (RBD) of the SARS-CoV, EG.5.1, and JN.1. However, the 5-HI maintained the binding with RBD and prevented the binding between hACE2 and RBD (IC
50
for the RBD of SARS-CoV, 1.067 nM; EG.5.1, 0.423 nM; JN.1, 0.223 nM). In neutralization assays with the authentic virus, we found that the 5-HI effectively neutralized Omicron variants XBB.1.5 (IC
50
, 0.308 nM), EG.5.1 (IC
50
, 0.129 nM), and JN.1 (IC
50
, 13.692 nM), while its parental antibodies showed weakened or no neutralization. Therefore, the 5-HI represents a promising candidate for further development in the treatment and prevention of ongoing evolved SARS-CoV-2 VOCs and other SARSr-CoVs that potentially emerge in the future.</description><identifier>ISSN: 0300-8584</identifier><identifier>ISSN: 1432-1831</identifier><identifier>EISSN: 1432-1831</identifier><identifier>DOI: 10.1007/s00430-024-00809-9</identifier><identifier>PMID: 39520579</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Antibodies ; Antibodies, Bispecific - immunology ; Antibodies, Bispecific - pharmacology ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - immunology ; Biomedical and Life Sciences ; Biomedicine ; Bispecific antibodies ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; COVID-19 - virology ; COVID-19 infection ; domain ; Humans ; Immunoglobulins ; Immunology ; inhibitory concentration 50 ; median effective concentration ; Medical Microbiology ; neutralization ; Neutralization Tests ; Protein Engineering ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome coronavirus 2 ; Severe acute respiratory syndrome-related coronavirus ; Severe acute respiratory syndrome-related coronavirus - immunology ; Spike Glycoprotein, Coronavirus - immunology ; Virology ; viruses</subject><ispartof>Medical microbiology and immunology, 2024-12, Vol.213 (1), p.24-24, Article 24</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>Copyright Springer Nature B.V. Dec 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c289t-5f830a5f836b6c0c0edc35eff055787e382af1c38aec37962e66f3c309957c453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00430-024-00809-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00430-024-00809-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39520579$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Fangfang</creatorcontrib><creatorcontrib>Wu, Qian</creatorcontrib><creatorcontrib>Hu, Yabin</creatorcontrib><creatorcontrib>Pan, Zhendong</creatorcontrib><creatorcontrib>Liu, Yong-Chen</creatorcontrib><creatorcontrib>Li, Yue-Zhou</creatorcontrib><creatorcontrib>Bostina, Mihnea</creatorcontrib><creatorcontrib>Liu, Wenpei</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><creatorcontrib>Qu, Xiaowang</creatorcontrib><creatorcontrib>Li, Yi-Ping</creatorcontrib><title>Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses</title><title>Medical microbiology and immunology</title><addtitle>Med Microbiol Immunol</addtitle><addtitle>Med Microbiol Immunol</addtitle><description>The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). A bsAb 5-HI showed a high binding capability to the S1 subunit of spike and exhibited breadth and potency against pseudotyped SARS-CoV-2 variants of concerns (VOCs) and SARS-related-CoVs (SARSr-CoVs), with half maximal effective concentration (EC
50
) of 0.028–3.444 nM and 50% inhibitory concentration (IC
50
) of 0.008-0.800 nM. In addition, it retained neutralization potency against the peudotyped virus of recently prevalent JN.1 strain (IC
50
, 12.74 nM). We found that the parental antibodies showed weak or no binding to the receptor binding domain (RBD) of the SARS-CoV, EG.5.1, and JN.1. However, the 5-HI maintained the binding with RBD and prevented the binding between hACE2 and RBD (IC
50
for the RBD of SARS-CoV, 1.067 nM; EG.5.1, 0.423 nM; JN.1, 0.223 nM). In neutralization assays with the authentic virus, we found that the 5-HI effectively neutralized Omicron variants XBB.1.5 (IC
50
, 0.308 nM), EG.5.1 (IC
50
, 0.129 nM), and JN.1 (IC
50
, 13.692 nM), while its parental antibodies showed weakened or no neutralization. Therefore, the 5-HI represents a promising candidate for further development in the treatment and prevention of ongoing evolved SARS-CoV-2 VOCs and other SARSr-CoVs that potentially emerge in the future.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Bispecific - immunology</subject><subject>Antibodies, Bispecific - pharmacology</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - immunology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bispecific antibodies</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>COVID-19 infection</subject><subject>domain</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>inhibitory concentration 50</subject><subject>median effective concentration</subject><subject>Medical Microbiology</subject><subject>neutralization</subject><subject>Neutralization Tests</subject><subject>Protein Engineering</subject><subject>SARS-CoV-2 - immunology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Severe acute respiratory syndrome-related coronavirus</subject><subject>Severe acute respiratory syndrome-related coronavirus - immunology</subject><subject>Spike Glycoprotein, Coronavirus - immunology</subject><subject>Virology</subject><subject>viruses</subject><issn>0300-8584</issn><issn>1432-1831</issn><issn>1432-1831</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9rFDEUx4Modq3-Ax5kwEsv0ZdfM8mxLPUHFIS2eg3ZzJttym6yJjOVHvq_m9mtCh5KLwm893mfkPcl5C2DDwyg-1gApAAKXFIADYaaZ2TBpOCUacGekwUIAKqVlkfkVSk3AKxrObwkR8IoDqozC3J_FtchImbsm1UoO_RhCL5xcQyr1Acsza8wXjcYr130M5PR9bXgYt_s0ojR3zVu7UIsY3N5enFJl-kH5c2ty6E6yp7b1zNu3FgFPuUU3W3IU8HymrwY3Kbgm4f7mHz_dHa1_ELPv33-ujw9p55rM1I1aAFuPttV68ED9l4oHAZQqtMdCs3dwLzQDr3oTMuxbQfhBRijOi-VOCYnB-8up58TltFuQ_G42biIaSpWMCXrzmQrnoBy3UnFta7o-__QmzTlWD8yU60UWppZyA-Uz6mUjIPd5bB1-c4ysHOO9pCjrTnafY7W1KF3D-pptcX-78if4CogDkCprbjG_O_tR7S_AU41p-c</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Chang, Fangfang</creator><creator>Wu, Qian</creator><creator>Hu, Yabin</creator><creator>Pan, Zhendong</creator><creator>Liu, Yong-Chen</creator><creator>Li, Yue-Zhou</creator><creator>Bostina, Mihnea</creator><creator>Liu, Wenpei</creator><creator>Zhao, Ping</creator><creator>Qu, Xiaowang</creator><creator>Li, Yi-Ping</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20241201</creationdate><title>Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses</title><author>Chang, Fangfang ; Wu, Qian ; Hu, Yabin ; Pan, Zhendong ; Liu, Yong-Chen ; Li, Yue-Zhou ; Bostina, Mihnea ; Liu, Wenpei ; Zhao, Ping ; Qu, Xiaowang ; Li, Yi-Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c289t-5f830a5f836b6c0c0edc35eff055787e382af1c38aec37962e66f3c309957c453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Bispecific - immunology</topic><topic>Antibodies, Bispecific - pharmacology</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - immunology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bispecific antibodies</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>COVID-19 infection</topic><topic>domain</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>inhibitory concentration 50</topic><topic>median effective concentration</topic><topic>Medical Microbiology</topic><topic>neutralization</topic><topic>Neutralization Tests</topic><topic>Protein Engineering</topic><topic>SARS-CoV-2 - immunology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Severe acute respiratory syndrome-related coronavirus</topic><topic>Severe acute respiratory syndrome-related coronavirus - immunology</topic><topic>Spike Glycoprotein, Coronavirus - immunology</topic><topic>Virology</topic><topic>viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Fangfang</creatorcontrib><creatorcontrib>Wu, Qian</creatorcontrib><creatorcontrib>Hu, Yabin</creatorcontrib><creatorcontrib>Pan, Zhendong</creatorcontrib><creatorcontrib>Liu, Yong-Chen</creatorcontrib><creatorcontrib>Li, Yue-Zhou</creatorcontrib><creatorcontrib>Bostina, Mihnea</creatorcontrib><creatorcontrib>Liu, Wenpei</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><creatorcontrib>Qu, Xiaowang</creatorcontrib><creatorcontrib>Li, Yi-Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Medical microbiology and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Fangfang</au><au>Wu, Qian</au><au>Hu, Yabin</au><au>Pan, Zhendong</au><au>Liu, Yong-Chen</au><au>Li, Yue-Zhou</au><au>Bostina, Mihnea</au><au>Liu, Wenpei</au><au>Zhao, Ping</au><au>Qu, Xiaowang</au><au>Li, Yi-Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses</atitle><jtitle>Medical microbiology and immunology</jtitle><stitle>Med Microbiol Immunol</stitle><addtitle>Med Microbiol Immunol</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>213</volume><issue>1</issue><spage>24</spage><epage>24</epage><pages>24-24</pages><artnum>24</artnum><issn>0300-8584</issn><issn>1432-1831</issn><eissn>1432-1831</eissn><abstract>The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). A bsAb 5-HI showed a high binding capability to the S1 subunit of spike and exhibited breadth and potency against pseudotyped SARS-CoV-2 variants of concerns (VOCs) and SARS-related-CoVs (SARSr-CoVs), with half maximal effective concentration (EC
50
) of 0.028–3.444 nM and 50% inhibitory concentration (IC
50
) of 0.008-0.800 nM. In addition, it retained neutralization potency against the peudotyped virus of recently prevalent JN.1 strain (IC
50
, 12.74 nM). We found that the parental antibodies showed weak or no binding to the receptor binding domain (RBD) of the SARS-CoV, EG.5.1, and JN.1. However, the 5-HI maintained the binding with RBD and prevented the binding between hACE2 and RBD (IC
50
for the RBD of SARS-CoV, 1.067 nM; EG.5.1, 0.423 nM; JN.1, 0.223 nM). In neutralization assays with the authentic virus, we found that the 5-HI effectively neutralized Omicron variants XBB.1.5 (IC
50
, 0.308 nM), EG.5.1 (IC
50
, 0.129 nM), and JN.1 (IC
50
, 13.692 nM), while its parental antibodies showed weakened or no neutralization. Therefore, the 5-HI represents a promising candidate for further development in the treatment and prevention of ongoing evolved SARS-CoV-2 VOCs and other SARSr-CoVs that potentially emerge in the future.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>39520579</pmid><doi>10.1007/s00430-024-00809-9</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8584 |
| ispartof | Medical microbiology and immunology, 2024-12, Vol.213 (1), p.24-24, Article 24 |
| issn | 0300-8584 1432-1831 1432-1831 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3154183463 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Antibodies Antibodies, Bispecific - immunology Antibodies, Bispecific - pharmacology Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Biomedical and Life Sciences Biomedicine Bispecific antibodies Coronaviridae Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - virology COVID-19 infection domain Humans Immunoglobulins Immunology inhibitory concentration 50 median effective concentration Medical Microbiology neutralization Neutralization Tests Protein Engineering SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Severe acute respiratory syndrome-related coronavirus Severe acute respiratory syndrome-related coronavirus - immunology Spike Glycoprotein, Coronavirus - immunology Virology viruses |
| title | Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A17%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engineered%20bispecific%20antibodies%20with%20enhanced%20breadth%20and%20potency%20against%20SARS-CoV-2%20variants%20and%20SARS-related%20coronaviruses&rft.jtitle=Medical%20microbiology%20and%20immunology&rft.au=Chang,%20Fangfang&rft.date=2024-12-01&rft.volume=213&rft.issue=1&rft.spage=24&rft.epage=24&rft.pages=24-24&rft.artnum=24&rft.issn=0300-8584&rft.eissn=1432-1831&rft_id=info:doi/10.1007/s00430-024-00809-9&rft_dat=%3Cproquest_cross%3E3128745288%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3126438493&rft_id=info:pmid/39520579&rfr_iscdi=true |